RESEARCH-USE BIOSIMILAR ANTIBODY

Suvizumab

Monoclonal antibody · IgG1

HIV-1 gp120IgG1RUO

Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection.

TARGETHIV-1 gp120
YMonoclonal antibody
CATALOGSC-BS-139
CATALOG NUMBERSC-BS-139
MOLECULAR WEIGHTApprox. 146.38 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection.

Suvizumab is a recombinant research-use antibody directed against HIV-1 gp120.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte